Sucralfate

CHEMBL6067980 Phase 4 승인됨 Unknown
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

This medication forms a thick, paste-like coating that adheres directly to ulcers in the stomach and esophagus, acting as a protective barrier against acid and digestive enzymes while the tissue heals. It works locally without being absorbed into the bloodstream and is particularly useful for patients who cannot tolerate acid-suppressing medications.

치료 영역

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

This medication forms a thick, paste-like coating that adheres directly to ulcers in the stomach and esophagus, acting as a protective barrier against acid and digestive enzymes while the tissue heals. It works locally without being absorbed into the bloodstream and is particularly useful for patients who cannot tolerate acid-suppressing medications.

Yes, Sucralfate is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6067980. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.